Gujarat Themis Biosyn Ltd — earnings calls
1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.
Q1 FY27 earnings call
Gujarat Themis Biosyn reported Q1 FY27 revenue of INR43.8 crores, up 22.1% year-on-year, with EBITDA growing 49.4% to INR20.8 crores at a 47.5% margin. Management discussed two announced acquisitions, MicroBiopharm Japan and a portfolio of 13 brands from Sanofi France, describing plans to fund them through a mix of equity and debt. Management also addressed expanded fermentation capacity, the API block ramp-up, and a resolved dispute with Optimus Drugs.